Article
[Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
Annales de biologie clinique - 1 Jan 2000
Gendron Nicolas, Belhouachi Nabila, Morel Véronique, Azgui Zahia, Maloum Karim, Nguyen-Khac Florence, Cayuela Jean-Michel, Davi Frédéric, Merle-Béral Hélène, Chapiro Elise
Abstract excerpt
We report here the case of a sixty-eight-year old woman with chronic myeloid leukemia. Molecular techniques identified the presence of the rare e19a2 BCR-ABL1 transcript. The patient was treated by 1(st) generation tyrosine-kinase inhibitor (TKI) (imatinib). Disease monitoring was performed by cytogenetic analyses and quantification of the BCR-ABL1 transcript. After 3 months, the treatment was modified due to an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.